Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH

被引:0
|
作者
Fabian Pitoia
Erika Abelleira
Graciela Cross
机构
[1] University of Buenos Aires,Division of Endocrinology–Hospital de Clínicas
来源
Endocrine | 2017年 / 55卷
关键词
Thyroglobulin levels; Remnant ablation; Differentiated thyroid cancer; Excellent response; Preparation mode; Risk of recurrence;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of our study was to evaluate the prognostic value of stimulated thyroglobulin levels at the moment of remnant ablation for predicting an initial excellent or a structural incomplete response to treatment according to the risk of recurrence in patients with differentiated thyroid cancer. Patients were divided into two groups according to the preparation mode for remnant ablation (thyroid hormone withdrawal or recombinant human TSH). We included 219 patients followed-up for at least for 24 months after remnant ablation. The primary endpoint was the best response to initial therapy assessed in the first 9–18 months of follow-up. An excellent response was observed in 45.1 % of patients prepared after recombinant human TSH compared to 44.6 % of patients prepared after thyroid hormone withdrawal (P = NS). The cutoff value of thyroglobulin level after recombinant human TSH for predicting an excellent response was 8 ng/ml (n = 51), with a sensitivity of 73.9 %, and a positive predictive value of 61 %. It was similar for patients with low vs. intermediate to high risk of recurrence. This cutoff value for thyroglobulin level after thyroid hormone withdrawal was 22 ng/ml (n = 168), with a sensitivity of 94.7 % and a positive predictive value of 61.7 %. In the thyroid hormone withdrawal group the thyroglobulin cutoff level was 12 ng/ml for low-risk patients compared to 16 ng/ml for those with intermediate to high risk of recurrence (P = 0.003). The cutoff value of the thyroglobulin level for predicting a structural incomplete response to initial treatment was 20 ng/ml after rhTSH, with a negative predictive value of 91.4 %. This level was higher in thyroid hormone withdrawal group, and it was established at 25 ng/ml, with a negative predictive value of 97.7 %. The stimulated Tg level seems to be different depending on the preparation mode (rhTSH or THW) for RA. It has a high NPV to predict the absence of a structural incomplete response and it is also a good predictor of the initial excellent response and the NED status at the end of follow-up.
引用
收藏
页码:200 / 208
页数:8
相关论文
共 50 条
  • [1] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Pitoia, Fabian
    Abelleira, Erika
    Cross, Graciela
    ENDOCRINE, 2017, 55 (01) : 209 - 217
  • [2] Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
    Ha, Jeonghoon
    Kim, Min Hee
    Jo, Kwanhoon
    Lim, Yejee
    Bae, Ja Seong
    Lee, Sohee
    Kang, Moo Il
    Cha, Bong Yun
    Lim, Dong Jun
    MEDICINE, 2017, 96 (29)
  • [3] Is recombinant human TSH as effective as thyroid hormone withdrawal in the detection and treatment of metastatic differentiated thyroid cancer?
    Iervasi, Giorgio
    Bottoni, Antonio
    Filidei, Elena
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (06) : 633 - 635
  • [4] Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
    Pitoia, Fabian
    Marlowe, Robert J.
    Abelleira, Erika
    Faure, Eduardo N.
    Bueno, Fernanda
    Schwarzstein, Diego
    Julio Lutfi, Ruben
    Niepomniszcze, Hugo
    JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [5] Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis
    Fu, H.
    Ma, C.
    Tang, L.
    Wu, F.
    Liu, B.
    Wang, H.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (01): : 121 - 128
  • [6] Recombinant TSH or thyroid hormone withdrawal?: A comparison of I-131 remnant ablation rates in thyroid cancer patients
    Luster, M
    Ladenson, P
    Pacini, F
    Schlumberger, M
    Driedger, A
    Kloos, R
    Sherman, S
    Corone, C
    Haugen, B
    Lassmann, M
    Hänscheid, H
    Reiners, C
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S290 - S291
  • [7] PROTOCOL FOR THYROID REMNANT ABLATION AFTER RECOMBINANT TSH IN THYROID CARCINOMA
    Pitoia, Fabian
    El Tamer, Elias
    Eugenia Salvai, Maria
    Niepomniszcze, Hugo
    MEDICINA-BUENOS AIRES, 2009, 69 (02) : 148 - 152
  • [8] Is Thyroglobulin at Ablation a Good Predictor for Thyroid Remnant Size in Differentiated Thyroid Cancer?
    Martins, H. C.
    Costa, G.
    Silva, R.
    Gil, P.
    Isidoro, J.
    Pedroso de Lima, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S363 - S364
  • [9] I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal
    Hong, Chae Moon
    Kim, Choon-Young
    Son, Seung Hyun
    Jung, Ji-hoon
    Lee, Chang-Hee
    Jeong, Ju Hye
    Jeong, Shin Young
    Lee, Sang-Woo
    Lee, Jaetae
    Ahn, Byeong-Cheol
    ANNALS OF NUCLEAR MEDICINE, 2017, 31 (08) : 582 - 589
  • [10] I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal
    Chae Moon Hong
    Choon-Young Kim
    Seung Hyun Son
    Ji-hoon Jung
    Chang-Hee Lee
    Ju Hye Jeong
    Shin Young Jeong
    Sang-Woo Lee
    Jaetae Lee
    Byeong-Cheol Ahn
    Annals of Nuclear Medicine, 2017, 31 : 582 - 589